Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameter
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rise in the prevalence of cytomegalovirus infection
3.2.1.2 Growing awareness and introduction of new drug therapies
3.2.1.3 High prevalence of infectious diseases among AIDS patients
3.2.1.4 Upsurge in patient pool of CMV retinitis and congenital CMV infection
3.2.2 Industry pitfalls & challenges
3.2.2.1 Adverse effects associated with cytomegalovirus drugs
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter’s analysis
3.5.1 Supplier power
3.5.2 Buyer power
3.5.3 Threat of new entrants
3.5.4 Threat of substitutes
3.5.5 Industry rivalry
3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive positioning matrix
4.4 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Drug Type, 2018 – 2032 ($ Mn)
5.1 Key trends
5.2 Valganciclovir
5.3 Ganciclovir
5.4 Cidofovir
5.5 Foscarnet
5.6 Other drug types
Chapter 6 Market Estimates and Forecast, By Application, 2018 – 2032 ($ Mn)
6.1 Key trends
6.2 Stem cell transplantation
6.3 Organ transplantation
6.4 Congenital CMV infection
6.5 Other applications
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2018 – 2032 ($ Mn)
7.1 Key trends
7.2 Oral
7.3 Intravenous
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2018 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 E-commerce
Chapter 9 Market Estimates and Forecast, By Region, 2018 – 2032 ($ Mn)
9.1 Key trends, by region
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Chimerix, Inc.
10.2 Clinigen Group PLC
10.3 F. Hoffmann-La Roche Ltd
10.4 Fresenius Kabi
10.5 Genentech Inc.
10.6 Gilead Sciences, Inc.
10.7 Merck & Co. Inc
10.8 Mylan N.V
10.9 Pfizer, Inc.
10.10 Takeda Pharmaceuticals
10.11 Teva Pharmaceuticals Inc
10.12 Thermo Fisher Scientific Inc.
